美國批准莫德納 mRNA 流感疫苗供成人使用
U.S. Approves Moderna's mRNA Flu Vaccine for Adults
Updated at: August 10, 2026 at 02:45 AM
2026年8月5日，美國食品藥物管理局（FDA）批准了莫德納（Moderna）首款針對50歲及以上成人、基於mRNA技術的流感疫苗mFlusiva，寫下醫療史上的新頁。
On August 5, 2026, the U.S.
這項成就意義重大，因為不同於傳統透過雞蛋培養的流感疫苗，mRNA技術能顯著縮短製造時間。
FDA made medical history by approving mFlusiva, Moderna’s first mRNA-based influenza vaccine for adults aged 50 and older.
這種速度對於在流感病毒出現突變時即時更新疫苗至關重要。
This achievement is significant because, unlike traditional flu shots that are grown in chicken eggs, mRNA technology allows for much faster manufacturing.
該疫苗的審核過程早期曾面臨挑戰，包括FDA對測試方法提出的質疑。
This speed is crucial for updating vaccines if flu strains mutate unexpectedly.
然而，在一個獨立顧問委員會一致推薦後，疫苗才順利獲准上市。
The approval process faced early challenges, including initial pushback from the FDA over testing methodology.
對於50至64歲的成人，該疫苗在4萬名參與者的試驗數據支持下獲得正式批准；至於65歲及以上的長者，則是根據強效的免疫反應數據獲得加速核准。
However, after an independent advisory committee unanimously recommended the vaccine, the path was cleared for its release.
儘管達成了這項科學里程碑，該疫苗仍處於複雜的局勢中。
For adults aged 50 to 64, the approval is full, supported by trials involving 40,000 participants.
隨著疫苗懷疑論升溫，加上羅伯特·甘迺迪二世（Robert F.
For those 65 and older, it received accelerated approval based on strong immune response data.
部長等政治人物對mRNA技術提出質疑，mFlusiva的成功將取決於臨床效能與公眾信賴。
With vaccine skepticism rising and political figures like Secretary Robert F.
莫德納計畫於2026-2027年流感季期間配送疫苗，為高風險的年長族群提供一項關鍵的防護工具。
Kennedy Jr. questioning mRNA technology, the success of mFlusiva will depend on both clinical effectiveness and public trust.
